Can you take Lonapegsomatropin with UAD Otic?

Lonapegsomatropin has a major potential interaction with Acute Abdomen.

Treatment with somatropin and somatrogon is contraindicated in patients with acute critical illness due to any complications following open heart surgery, abdominal surgery, multiple trauma, or acute respiratory failure. Patients with these conditions have an increased risk of mortality.

Lonapegsomatropin has a moderate potential interaction with Adrenal Insufficiency.

Patients with or at risk for pituitary hormone deficiency(s) may experience reduced serum cortisol and/or unmasking of central (secondary) hypoadrenalism. Glucocorticoid replacement may require increased maintenance or stress doses. Monitor for reduced serum cortisol and/or the need for glucocorticoid dose increases.

Lonapegsomatropin has a major potential interaction with Bladder Cancer.

Somatropin and somatrogon are contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin and somatrogon should be discontinued if there is any evidence of recurrence.

Lonapegsomatropin has a major potential interaction with Brain Tumor.

Somatropin and somatrogon are contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin and somatrogon should be discontinued if there is any evidence of recurrence.

Lonapegsomatropin has a major potential interaction with Breast Cancer.

Somatropin and somatrogon are contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin and somatrogon should be discontinued if there is any evidence of recurrence.

The neomycin topical in UAD Otic has a moderate potential interaction with Burns, External.

Topical aminoglycosides should not be used on serious burns. When applied locally, aminoglycosides are generally not absorbed to a significant extent through intact skin but readily absorbed through denuded, burned, or granulating skin. Systemic adverse effects of aminoglycosides include nephrotoxicity and ototoxicity to vestibular and auditory functions. In general, topical aminoglycosides should not be used on large areas of the body or for more than 7 days without medical supervision.

The hydrocortisone otic in UAD Otic has a major potential interaction with Chronic Otitis Media.

The use of medications that are intended for the treatment of otitis externa or other conditions of the external ear canal should generally be avoided, or otherwise approached with caution, in patients with a perforated tympanic membrane due to the risk of toxicity from medication that may get into the middle ear. Caution is also advised in patients with longstanding, chronic otitis media because of the possibility of a perforated tympanic membrane in such patients.

Lonapegsomatropin has a moderate potential interaction with Diabetes Mellitus.

The use of growth hormone has been associated with resistance to insulin. Patients with diabetes mellitus or impaired glucose tolerance should be observed closely during therapy. The dose of antihyperglycemic drugs (insulin or oral/injectable agents) may require adjustment.

Lonapegsomatropin has a major potential interaction with Diabetic Retinopathy.

Somatropin, somatrogon , and lonapegsomatropin are contraindicated in patients with active proliferative or severe non-proliferative diabetic retinopathy since treatment may worsen condition.

The hydrocortisone otic in UAD Otic has a major potential interaction with Herpes Simplex Otitis Externa.

The use of otic preparations containing corticosteroids is contraindicated in patients with viral infections of the external canal including varicella and herpes simplex otitis externa. Corticosteroids may decrease host resistance to infectious agents, thus prolonging the course and/or exacerbating the severity of the infection while encouraging the development of new or secondary infection. Normally, corticosteroids may be administered with caution provided it is accompanied by appropriate anti-infective agents. However, otic preparations that are currently available lack effective antiviral agents.

Lonapegsomatropin has a major potential interaction with Lung Cancer.

Somatropin and somatrogon are contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin and somatrogon should be discontinued if there is any evidence of recurrence.

Lonapegsomatropin has a moderate potential interaction with Papilledema Associated with Increased Intracranial Pressure.

Intracranial hypertension with papilledema, visual changes, nausea and/or vomiting has been reported in a small number of patients treated with somatropin, somatrogon , and lonapegsomatropin . Fundoscopic examination should be performed before treatment initiation to exclude preexisting papilledema, and should be continued periodically during treatment. If papilledema is observed during treatment, therapy should be stopped. Treatment could be restarted at a lower dose once intracranial hypertension has been resolved. Patients with Turner Syndrome might be at increased risk of developing intracranial hypertension.

The neomycin topical in UAD Otic has a major potential interaction with Perforated Tympanic Membrane.

Like other aminoglycosides, neomycin is potentially ototoxic, both to vestibular and to auditory functions. Therapy with neomycin otic preparations should be administered cautiously in patients with chronic otitis media or a perforated tympanic membrane. The risk of ototoxicity may be increased if medication enters the middle ear.

The hydrocortisone otic in UAD Otic has a major potential interaction with Perforated Tympanic Membrane.

The use of medications that are intended for the treatment of otitis externa or other conditions of the external ear canal should generally be avoided, or otherwise approached with caution, in patients with a perforated tympanic membrane due to the risk of toxicity from medication that may get into the middle ear. Caution is also advised in patients with longstanding, chronic otitis media because of the possibility of a perforated tympanic membrane in such patients.

Lonapegsomatropin has a major potential interaction with Prostate Cancer.

Somatropin and somatrogon are contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin and somatrogon should be discontinued if there is any evidence of recurrence.

Lonapegsomatropin has a major potential interaction with Pulmonary Impairment.

Treatment with somatropin and somatrogon is contraindicated in patients with acute critical illness due to any complications following open heart surgery, abdominal surgery, multiple trauma, or acute respiratory failure. Patients with these conditions have an increased risk of mortality.

Lonapegsomatropin has a major potential interaction with Pulmonary Impairment.

Somatropin and somatrogon is contraindicated in patients with Prader-Willi Syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients.

The hydrocortisone otic in UAD Otic has a major potential interaction with Ramsay Hunt Syndrome.

The use of otic preparations containing corticosteroids is contraindicated in patients with viral infections of the external canal including varicella and herpes simplex otitis externa. Corticosteroids may decrease host resistance to infectious agents, thus prolonging the course and/or exacerbating the severity of the infection while encouraging the development of new or secondary infection. Normally, corticosteroids may be administered with caution provided it is accompanied by appropriate anti-infective agents. However, otic preparations that are currently available lack effective antiviral agents.

Lonapegsomatropin has a moderate potential interaction with Scoliosis.

Progression of scoliosis can occur in patients who experience rapid growth. Since somatropin and somatrogon increase growth rate, children with a history of scoliosis should be monitored for progression of this condition. Physicians should be alert for this skeletal abnormality which can be commonly seen in patients with Turner and Prader-Willi syndromes, and can manifest during somatropin and somatrogon treatment.

Lonapegsomatropin has a major potential interaction with Sepsis.

Treatment with somatropin and somatrogon is contraindicated in patients with acute critical illness due to any complications following open heart surgery, abdominal surgery, multiple trauma, or acute respiratory failure. Patients with these conditions have an increased risk of mortality.

Lonapegsomatropin has a major potential interaction with Skin Cancer.

Somatropin and somatrogon are contraindicated in the presence of any active malignancy. Any preexistent malignancy should be inactive and its treatment should be completed prior to somatropin therapy. This includes the presence of any intracranial tumor. Somatropin and somatrogon should be discontinued if there is any evidence of recurrence.

Lonapegsomatropin has a major potential interaction with Sleep Apnea.

Somatropin and somatrogon is contraindicated in patients with Prader-Willi Syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients.

Lonapegsomatropin has a moderate potential interaction with Underactive Thyroid.

The use of growth hormone has been associated with the development of hypothyroidism. Patients should be monitored baseline and periodically for adequate thyroid function. Inadequate treatment of hypothyroidism may inhibit the optimal response to growth hormone.

Lonapegsomatropin has a major potential interaction with Weight Loss.

Somatropin and somatrogon is contraindicated in patients with Prader-Willi Syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was used in such patients.